Magee W E, Talcott M L, Straub S X, Vriend C Y
Biochim Biophys Acta. 1976 Dec 21;451(2):610-8. doi: 10.1016/0304-4165(76)90156-2.
Intravenous injection of negatively and positively charged liposomes containing entrapped poly(I)-poly(C) induced a vigorous interferon response in mice with serum titers of interferon reaching twenty times those observed with comparable dosages of free poly(I)-poly(C). The response did not persist over an extended time period as observed earlier for enhanced interferon production stimulated by positively charged liposomes containing the inducer. Both negatively and positively charged liposomes containing [14C]poly(I)-poly(C) were taken up chiefly by the liver when given intravenously. Negatively charged particles were concentrated somewhat preferentially by the spleen (7--9% of the dose compared to 4--6%). Less radioactivity was found in liver and spleen when negatively charged particles were given intraperitoneally than was the case when positively charged particles were injected by this route. Free [14C]poly(I)-poly(C) was extensively metabolized to low molecular weight materials within four hours of injection, while encapsulation of the polymer provided protection against in vivo degradation. When both preferential localization and protection were considered, from three to five times as much high molecular weight E114C]poly(I)-poly(C) was recovered from liver at four hours after intravenous injection when the compound was given in encapsulated form compared to free polymer. Similarly, for spleen, seven times and three times as much polymeric [14C]poly(I)-poly(C) was recovered following injection of negatively charged liposomes and positively charged liposomes respectively compared to free [14C]poly(I)-poly(C). At 48 h after an intravenous injection of positively charged liposomes, as much as four percent of the dose remained in high molecular weight form in the liver and one percent in the spleen. Following intraperitoneal injections, polymeric [14C]poly(I)-poly(C) recovered from the liver never exceeded 4.3% of the dose, showing that most of the radioactivity in the liver consisted of metabolites. These results suggest that elevated and prolonged production of interferon in animals treated with encapsulated inducer results from a combination of factors including preferential tissue location and protection of the inducer from hydrolytic cleavage.
静脉注射包封有聚肌苷酸 - 聚胞苷酸(poly(I)-poly(C))的带负电荷和正电荷的脂质体,可在小鼠中诱导强烈的干扰素反应,血清干扰素滴度达到用相当剂量的游离聚肌苷酸 - 聚胞苷酸所观察到的滴度的20倍。与早期观察到的含诱导剂的带正电荷脂质体刺激的干扰素产生增强的情况不同,该反应不会在较长时间内持续。静脉注射时,含[14C]聚肌苷酸 - 聚胞苷酸的带负电荷和正电荷的脂质体主要被肝脏摄取。带负电荷的颗粒在脾脏中略有优先富集(剂量的7 - 9%,而游离聚肌苷酸 - 聚胞苷酸为4 - 6%)。与通过该途径注射带正电荷颗粒的情况相比,腹腔注射带负电荷颗粒时,肝脏和脾脏中的放射性较低。游离[14C]聚肌苷酸 - 聚胞苷酸在注射后4小时内被广泛代谢为低分子量物质,而聚合物的包封提供了对体内降解的保护。当考虑到优先定位和保护这两个因素时,静脉注射4小时后,与游离聚合物相比,以包封形式给予化合物时,从肝脏中回收的高分子量[14C]聚肌苷酸 - 聚胞苷酸是其三到五倍。同样,对于脾脏,与游离[14C]聚肌苷酸 - 聚胞苷酸相比,注射带负电荷脂质体和带正电荷脂质体后分别回收的聚合物[14C]聚肌苷酸 - 聚胞苷酸是其七倍和三倍。静脉注射带正电荷脂质体48小时后,高达4%的剂量仍以高分子量形式存在于肝脏中,1%存在于脾脏中。腹腔注射后,从肝脏中回收的聚合物[14C]聚肌苷酸 - 聚胞苷酸从未超过剂量的4.3%,这表明肝脏中的大部分放射性由代谢物组成。这些结果表明,用包封诱导剂处理的动物中干扰素产生的升高和延长是由多种因素共同作用的结果,包括诱导剂的优先组织定位和免受水解裂解的保护。